The Netflix Model for Medicines: How Delinked Subscription Payment Works

Delinked payment separates what a health system pays a drug company from how much of the drug is actually used. Instead of buying pills by the box, the payer buys access for a flat annual fee. The United Kingdom now does exactly this for new antibiotics through the Antimicrobial Products Subscription Model. It is nicknamed the Netflix model because, as with a streaming subscription, the price is the same whether you watch one film or a hundred. NHS England pays a fixed yearly sum for a qualifying antibiotic no matter how many patients receive it, so the manufacturer earns a predictable return while clinicians stay free to hold the drug back for the cases that truly need it. According to NICE and the House of Commons Library, in 2024 the UK made this the first permanent scheme of its kind anywhere.

Key points#

• Delinkage means revenue is decoupled from sales volume: a fixed fee replaces per-unit payment.
• It exists to solve a specific problem in antibiotics, where the most valuable new drugs are the ones we most want to keep unused.
• NICE grades each antibiotic into a value band; NHS England then pays a flat annual subscription tied to that band.
• The UK piloted the idea from 2022, then made it permanent in 2024.
• A one-off 2019 hepatitis C deal used the same volume-price logic, but for the opposite goal: treating more people, not fewer.

Why antibiotics break the usual pricing rules#

For almost every medicine, paying by the unit works fine. A company that makes a useful drug sells more of it, earns more, and reinvests in the next one. Supply and demand line up. Antibiotics are the strange case where that alignment breaks down.

Consider a new antibiotic that can defeat bacteria nothing else can touch. Its value to society is highest precisely when it is used least. Careful stewardship means reserving such an agent as a last resort, so that resistance to it develops as slowly as possible. That is good medicine. It is also a business disaster. A firm can spend a decade and a fortune bringing that drug to market, only to watch the health system deliberately leave it on the shelf. Under per-unit pricing, a drug kept in reserve is a drug that never pays for itself.

The results have not been hypothetical. The House of Commons Library notes that several companies which launched genuinely new antibiotics went bankrupt or abandoned the field altogether, and the pipeline of new antimicrobials has thinned even as drug-resistant infections climb. The incentive to develop the very medicines resistance will one day demand has been draining away.

Push versus pull, and where delinkage fits#

Economists sort the fixes into two families. A push incentive lowers the cost of doing the work up front: research grants, tax relief, subsidised trials. A pull incentive rewards the finished product, telling industry that if you build something valuable, a buyer will be waiting. The two are complementary, but they solve different halves of the problem.

Delinkage is a pull incentive. It does not pay a company to sell more antibiotic; it pays for the antibiotic simply to exist and be ready. That distinction is the whole point. By promising a return for availability rather than for volume, it lets a manufacturer profit from a drug that good practice keeps in reserve.

How the UK subscription model actually runs#

The mechanism comes in two moves: first value the drug, then pay a fixed price matched to that value.

NICE handles the valuation. Commissioned by NHS England, it convenes an expert panel that scores each antimicrobial against defined criteria, weighing its worth to the whole health and care system rather than to a single prescription. As NICE describes on its own site, that assessment sorts a product into one of four value bands. According to NHS England's guidance on commercial arrangements, each band carries a fixed annual subscription fee for England, running from 5 million pounds for an important new antimicrobial up to 20 million pounds for a breakthrough one, with the two middle bands set at 10 million and 15 million pounds.

Once the band is fixed, NHS England pays that flat fee every year for access, and the sum never moves with prescription counts. Contracts run for an initial term with options to extend across the product's exclusivity window. Because the money is locked in, two temptations disappear at once. The manufacturer has no reason to push for wider use, and the health system faces no per-dose cost that might discourage careful reserving. The pressure to oversell and the pressure to overuse cancel out together.

The programme started small. NHS England awarded its first two subscription-style contracts in July 2022, for cefiderocol and for ceftazidime with avibactam, each at a fixed fee reported around 10 million pounds a year. After public consultation, the government approved the move from pilot to permanent scheme on 8 May 2024. NHS England has since outlined an expanded version covering all four UK nations, with a considerably larger budget for new contracts, a fresh round of NICE-led evaluations, and further contracts expected from 2026. Forward-looking figures are best read as the published plan rather than settled fact, since procurement rounds and budgets get revised over time.

The hepatitis C deal: same tool, opposite aim#

Delinkage is now bound up with antibiotics, but the UK reached for the same underlying idea once before, and for a nearly opposite purpose. In 2019 NHS England struck an agreement with the makers of direct-acting antiviral cures for hepatitis C. This time the goal was not to hold treatment back but to pour it out, aiming to eliminate the infection as a public health problem.

The common thread is breaking the tie between price and volume. As NHS England announced, the deal secured the new hepatitis C medicines at agreed prices, giving the system the budget certainty to hunt down and treat as many undiagnosed patients as possible without each extra cure adding unpredictable cost. The contrast with antibiotics is biological. These antivirals cure the disease outright, so treating more people shrinks tomorrow's patient pool rather than breeding resistance. Delinkage fit both cases, but it was steering toward restraint in one and toward maximum reach in the other.

What delinkage settles, and what it leaves open#

Delinkage is a payment reform, and it only reaches as far as the problem it was built for. It can rebuild a business case for keeping valuable antibiotics on hand and can put payment and stewardship on the same side. It does not, on its own, invent new science, guarantee that any particular candidate ever reaches patients, or answer how much a health system should spend in total.

Several judgement calls stay genuinely contested. Pricing an antibiotic that is meant to sit mostly unused is inherently hard, and thoughtful analysts disagree over whether the UK bands are generous enough to shift global research decisions. Scale is another open question. One country's national subscription is a small slice of what a truly worldwide pull incentive would need to be, and coordinated international action has proved stubbornly difficult to organise. These are trade-offs for you to weigh rather than settled verdicts.

What the UK scheme does show is that a payer can buy readiness instead of consumption, and can do it through a transparent, criteria-based process. Whether that is enough to refill the antibiotic pipeline is a question the next several years, and the wider international response, will have to answer.